Intravitreal Triamcinolone Acetonide Injection for Treatment of Refractory Diabetic Macular Edema A Systematic Review

被引:89
作者
Yilmaz, Taygan [1 ]
Weaver, Christopher D. [1 ]
Gallagher, Micheal J. [2 ]
Cordero-Coma, Miguel [3 ]
Cervantes-Castaneda, Rene A. [4 ]
Klisovic, Dino [5 ]
Lavaque, Alejandro J. [6 ]
Larson, Robin J. [1 ]
机构
[1] Dartmouth Inst Hlth Policy & Clin Practice, Hanover, NH 03766 USA
[2] Hermitage Med Clin, Dublin, Ireland
[3] Hosp Leon, Dept Ophthalmol, Leon, Spain
[4] CODET Vis Inst, Tijuana, Mexico
[5] Ohio State Univ, Columbus, OH 43210 USA
[6] Oftalmol Cristo Alvarez, San Miguel De Tucuman, Argentina
关键词
RANDOMIZED CLINICAL-TRIAL; RETINOPATHY; PHOTOCOAGULATION;
D O I
10.1016/j.ophtha.2009.02.002
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Objective: To compare intravitreal triamcinolone acetonide (IVTA) injection versus no treatment or sub-Tenon triamcinolone acetonide (STTA) injection in improving visual acuity (VA) of patients with refractory diabetic macular edema (DME; unresponsive to focal laser therapy). Clinical Relevance: Diabetic macular edema is the leading cause of visual loss in diabetic retinopathy. Laser therapy has been the standard of care for patients with persistent or progressive disease. More recently, it has been suggested that IVTA injection may improve VA. Methods and Literature Reviewed: The following databases were searched: Medline (1950-September Week 2 2008), The Cochrane Library (Issue 3, 2008), and the TRIP Database (up to September 1, 2008), using no language or other limits. Randomized controlled trials were included that consisted of patients with refractory DME, those comparing IVTA injection with no treatment or STTA injection, those reporting VA outcomes, and those having a minimum follow-up of 3 months. Results: In the 4 randomized clinical trials comparing IVTA injection with placebo or no treatment, IVTA injection demonstrated greater improvement in VA at 3 months, but the benefit was no longer significant at 6 months. Those who received IVTA injection had significantly higher IOP at 3 months and at 6 months. In the 2 randomized clinical trials comparing IVTA injection with STTA injection, IVTA injection demonstrated greater improvement in VA at 3 months, but not at 6 months. Intravitreal triamcinolone acetonide injection demonstrated no difference in IOP at 3 months or at 6 months. Conclusions: Intravitreal triamcinolone acetonide injection is effective in improving VA in patients with refractory DME in the short-term, but the benefits do not seem to persist in the long-term. Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2009;116:902-913 (C) 2009 by the American Academy of Ophthalmology.
引用
收藏
页码:902 / 911
页数:10
相关论文
共 25 条
  • [1] Intravitreal triamcinolone for uveitic cystoid macular edema: An optical coherence tomography study
    Antcliff, RJ
    Spalton, DJ
    Stanford, MR
    Graham, EM
    Ffytche, TJ
    Marshall, J
    [J]. OPHTHALMOLOGY, 2001, 108 (04) : 765 - 772
  • [2] Primary intravitreal bevackumab (Avastin) for diabetic macular edema - Results from the Pan-American Collaborative Retina Study Group at 6-month follow-up
    Arevalo, J. Fernando
    Fromow-Guerra, Jans
    Quiroz-Mercado, Hugo
    Sanchez, Juan G.
    Wu, Lihteh
    Maia, Mauricio
    Berrocal, Maria H.
    Solis-Vivancol, Adriana
    Farah, Michel E.
    [J]. OPHTHALMOLOGY, 2007, 114 (04) : 743 - 750
  • [3] Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6-month results of a prospective controlled trial
    Audren, Francois
    Erginay, Ali
    Haouchine, Belkacem
    Benosman, Rym
    Conrath, John
    Bergmann, Jean-Francois
    Gaudric, Alain
    Massin, Pascale
    [J]. ACTA OPHTHALMOLOGICA SCANDINAVICA, 2006, 84 (05): : 624 - 630
  • [4] Intravitreal injection versus sub-Tenon's infusion of triamcinolone acetonide for refractory diabetic macular edema: A randomized clinical trial
    Bonini, MA
    Jorge, R
    Barbosa, JC
    Calucci, D
    Cardillo, JA
    Costa, RA
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2005, 46 (10) : 3845 - 3849
  • [5] Comparison of intravitreal versus posterior sub-tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema
    Cardillo, JA
    Melo, LAS
    Costa, RA
    Skaf, M
    Belfort, R
    Souza-Filho, AA
    Farah, ME
    Kuppermann, BD
    [J]. OPHTHALMOLOGY, 2005, 112 (09) : 1557 - 1563
  • [6] A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema
    Chun, Dal W.
    Heier, Jeffrey S.
    Topping, Trexler M.
    Duker, Jay S.
    Bankert, Joy M.
    [J]. OPHTHALMOLOGY, 2006, 113 (10) : 1706 - 1712
  • [7] A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema
    Cunningham, ET Jr
    Adamis, AP
    Altaweel, M
    Aiello, LP
    Bressler, NM
    D'Amico, DJ
    Goldbaum, M
    Guyer, DR
    Katz, B
    Patel, M
    Schwartz, SD
    [J]. OPHTHALMOLOGY, 2005, 112 (10) : 1747 - 1757
  • [8] Dehghan Mohammad H., 2008, International Ophthalmology, V28, P7, DOI 10.1007/s10792-007-9097-y
  • [9] SYSTEMATIC REVIEWS - IDENTIFYING RELEVANT STUDIES FOR SYSTEMATIC REVIEWS
    DICKERSIN, K
    SCHERER, R
    LEFEBVRE, C
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1994, 309 (6964): : 1286 - 1291
  • [10] ELMAN MJ, 2008, OPHTHALMOLOGY, V115, pE1